New VIDI investigator tracks down the cells and molecules used by human immune system to battle invasive fungal infections to improve care for immunocompromised patients
Aug. 24, 2009
Dr. Tobias Hohl came to the Fred Hutchinson Cancer Research Center's Vaccine and Infectious Disease Institute in May with a mission: to track down the cells and molecules used by human immune system to battle invasive fungal infections, in an effort to improve care for immunocompromised patients who contract fungal diseases. Hohl's win of a Young Investigator Award from the American Society for Microbiology in July underscores his progress in a challenging field—challenging because, compared to bacterial and viral pathogens, fungal diseases are understudied and difficult to diagnose and treat.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.